Kronos Bio, Inc.

Kronos Bio, Inc. (KRON) priced its initial public offering on Oct 9, 2020 at $19.00 per share, above its $16.00–$18.00 range, raising $250M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.01B. Goldman Sachs was lead-left underwriter, joined by Jefferies, TD Cowen and Piper Sandler. Cooley advised the company and Latham & Watkins advised the underwriters.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company developing cancer therapeutics that target dysregulated transcription factors and their regulatory networks. Its lead candidate, entospletinib, an oral SYK inhibitor tested in 148 acute myeloid leukemia patients, is planned for a registrational Phase 2/3 trial in 2021.

Status

IPO

Ticker

KRON

Exchange

Nasdaq Global Select

Priced

Oct 9, 2020

IPO price

$19.00

Price range

$16.00–$18.00

Raised

$250M

Market cap at IPO price

$1.01B

First filed

Sep 18, 2020

Underwriters

Goldman Sachs, Jefferies, TD Cowen and Piper Sandler

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.